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Abstract: Cardiac conduction disease (CCD), which causes altered electrical impulse propagation in
the heart, is a life-threatening condition with high morbidity and mortality. It exhibits genetic and
clinical heterogeneity with diverse pathomechanisms, but in most cases, it disrupts the synchronous
activity of impulse-generating nodes and impulse-conduction underlying the normal heartbeat. In
this study, we investigated a consanguineous Pakistani family comprised of four patients with CCD.
We applied whole exome sequencing (WES) and co-segregation analysis, which identified a novel
homozygous missense mutation (c.1531T>C;(p.Ser511Pro)) in the highly conserved kinase domain
of the cardiac troponin I-interacting kinase (TNNI3K) encoding gene. The behaviors of mutant and
native TNNI3K were compared by performing all-atom long-term molecular dynamics simulations,
which revealed changes at the protein surface and in the hydrogen bond network. Furthermore,
intra and intermolecular interaction analyses revealed that p.Ser511Pro causes structural variation in
the ATP-binding pocket and the homodimer interface. These findings suggest p.Ser511Pro to be a
pathogenic variant. Our study provides insights into how the variant perturbs the TNNI3K structure-
function relationship, leading to a disease state. This is the first report of a recessive mutation in
TNNI3K and the first mutation in this gene identified in the Pakistani population.
Keywords: TNNI3K; missense mutation; molecular modeling simulation; cardiac conduction
1. Introduction
Cardiac conduction disease (CCD) is a hypernym that encompasses numerous rare
disorders in which the integrity of the heart conduction system is disrupted [1]. In CCD,
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anatomical or functional alterations in the conduction system lead to slowing or blocking of
impulse induction, which can cause syncope or sudden death. Structural CCD with abnor-
mal impulse propagation is most often a secondary impact of congenital heart disease or
histological heart abnormalities [1,2]. Physiologically, CCD is primarily due to dysfunction
of the sinoatrial node (SAN), atrioventricular node (AVN), His-bundle, the right or left
bundle branch (RBB or LBB) Purkinje system, or the peripheral ventricular conduction
system (PVCS) [3,4]. The molecular and cellular mechanisms underlying CCD are diverse;
however, regardless of its cause, pacemaker therapy is a potential cure. Understanding of
genetic contributions to cardiac electrophysiology has been advanced by familial clustering
and GWAS studies, although the latter approach has had limited success in identification
of genetic variants associated with phenotypic consequences [5,6].
Familial aggregation of conduction system diseases has been highly valuable in uncov-
ering the molecular mechanisms underlying CCD and establishing phenotype-genotype
correlations [4,6]. Most conduction diseases are inherited in an autosomal dominant
manner; however, a few rare homozygous mutations have revealed recessive inheritance
patterns [6,7]. Pedigree and large cohort studies have been used successfully to identify
causative genes implicated in dysrhythmias and conduction disorders [6–8]. To date, the
identified genes harboring rare variant encoding proteins with diverse functions include
ion channels, circulating hormones, cardiac transcription factors, and structural proteins
such as SCN5A (MIM 600163), SCN1B (MIM 600235), KCNK17 (MIM 607370), KCNQ1
(MIM 607542), NPPA (MIM 108780), CX40 (MIM 121013), TRPM4 (MIM 606936), NKX2.5
(MIM 1 600584), LMNA (MIM 150330), and TNNI3K (MIM 613932) [9–17].
The human cardiac troponin I-interacting kinase (TNNI3K) gene maps to chromosome
1p31.1, comprises 25 exons, and encodes a protein of 835 amino acids, with a molecular
mass of 93 kDa [18]. TNNI3K is a dual-functional (serine/threonine and tyrosine) kinase
that modulates its target proteins by transferring a phosphate group from ATP on to the
hydroxyl group of Ser or Thr (during Ser/Thr kinase activity) or Tyr (during Tyr kinase
activity). TNNI3K contains four domains: an N-terminal coiled-coil domain (amino acids
(aa) 21–51); ten ankyrin (ANK) repeats in the amino terminus (aa 66–410); a central active
kinase domain (aa 463–723); and a COOH-terminal serine-rich domain (aa 733–746) [18].
Furthermore, TNNI3K has numerous functional binding sites in its molecular structure,
including those for ATP (Ser499), magnesium (site unknown), cardiac troponin I (cTnI)
(site unknown), MEF2 (aa 147–157), TBX5 (aa 74–89), SRE (aa 82–96), M-CAT box (aa
120–135), and GATA4 (aa 160–169), indicating that it has many interacting partners [18,19].
Among these interacting proteins, cTnI (mutant forms of which can cause hypertrophic
cardiomyopathy) directly interacts with TNNI3K [19] Furthermore, homology search
and phylogenetic analysis indicate that TNNI3K belongs to a tyrosine kinase-like (TLK)
group within the mixed lineage kinase (MLK) kinase kinase (MAPKKKS or MAP3K)
family in the human kinome tree [20,21]. The regulation and activation of MAP3K kinases
are poorly understood; however, several of them, including MEKK2 (MAP/ERK kinase
kinase 2), dual leucine zipper-bearing kinase (DLK), apoptosis signal-regulating kinase 1
(ASK1), and integrin-linked kinase (ILK), form dimers or oligomers in response to upstream
stimuli and these dimeric/oligomeric states are considered essential for downstream
signal transduction [21,22]. TNNI3K can form homodimers or oligomers that lead to
its self-phosphorylation and activation. The N-terminal ANK domain is necessary for
autophosphorylation, while the C-terminal domain negatively regulates kinase activity [21].
TNNI3K is a cardiomyocyte-specific protein kinase with key roles in cardiac contrac-
tility, hypertrophic remodeling, and cardiac differentiation, and helps to repair cardiac
injury by suppressing cTnI, which facilitates the maintenance of heartbeat rhythm and
contractual force [23,24]. Mutations in TNNI3K have been linked to numerous cardiac
phenotypes including cardiac conduction, atrial/junctional tachycardia, dilated cardiomy-
opathy, and heart failure [16,25–27]. In a mouse model, Tnni3k knock-out resulted in en-
hanced cardiomyocyte proliferation following injury, while overexpression of the molecule
in zebrafish had different effects, including stimulation of cardiomyocyte polyploidy and
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impairment of cardiac regeneration [28]. To date, five single nucleotide variants have
been reported in human TNNI3K. Among them, three missense, one splicing, and one
nonsense mutation were reported in different patients from Germany, Canada, Salvador,
and China [16,25–27]. Here, we report a novel recessive missense variant in TNNI3K
(NM_015978.2: c.1531T>C) in a Pakistani family, which was not present in the Human
Gene Mutation Database (HGMD) or any other publicly accessible databases.
2. Materials and Methods
2.1. Human Subjects, DNA Extraction, and Clinical Evaluation
A four-generation consanguineous family with conduction heart disease was recruited
from Swat, Khyber Pukhtunkhwa, Pakistan (Figure 1a). Written informed consent was
obtained from all adult individuals and the parents of patients. Blood samples from two
affected and four unaffected individuals were obtained in ethylenediaminetetraacetic acid-
containing BD vacutainers® (BD-Plymouth, Plymouth, UK). DNA from blood samples was
isolated using the Qiamp DNA FFPE Tissue kit (Qiagen, Hilden, Germany). Phenotypic as-
sessment and diagnoses were conducted in two living symptomatic family members based
on cardiological investigations and clinical data. Rhythm and conduction abnormalities
were detected by a standard 24 h Holter electrocardiogram (ECG) and 12-lead surface ECG
(speed 25 mm/s, 10 mm/mV). Echocardiography was performed to check for problems
with the valves or chambers of the heart.




Figure 1. Pedigree, sequencing chromatogram, and location of the TNNI3K variant in the family 
with cardiac conduction disease (CCD). (a) Family pedigree. The open symbols represent unaffected 
individuals and the filled symbols represent affected individuals; symbols with a diagonal line rep-
resent deceased individuals; and the arrowhead designates the proband. An asterisk indicates fam-
ily members from whom DNA was available. The genotypes of the TNNI3K mutation are indicated 
below each examined member: CC (homozygote); TC (heterozygote); number inside the circle de-
note the number of individuals. (b) Sequencing chromatograms. Vertical arrows indicate the muta-
tion site. (c) Schematic of the human TNNI3K gene. The positions of coding exons (black) and UTRs 
(white) are indicated. Black arrows indicate previously reported pathogenic variants and the red 
arrow shows the novel variant c.1531T>C in exon 16. (d) Initial 3D structure of TNNI3K-WT (PDB-
ID: 4YFI [29]) shown as a ribbon. Monomer I is shown in gray and monomer II in green. The Cα 
atoms of Ser511 (red), Gly526 (blue), and Thr539 (blue) of monomer I are shown in spheres relative 
to the ATP-binding pocket (orange surface) of monomer I. Gly526 and Thr539 are known TNNI3K 
missense variants. (e) TNNI3K protein domain structure. Coiled coil domain (gray); functional 
ankyrin repeat domains, ANK1–ANK10 (purple); kinase domain (orange), where the homozygous 
mutation p.Ser511Pro resides (arrowed); and a serine-rich domain (spring green).  
2.2. Whole Exome Capture and Sequencing 
WES of two of the affected individuals (IV-3 and IV-5), their non-affected siblings 
(1V-4 and IV-6), and their parents (III-1 and III-2) (Figure 1a) were carried out at the Co-
logne Center for Genomics (CCG, University of Cologne, Cologne, Germany). A genomic 
DNA sample (1 µg) was sheared by fragmentation (Covaris, Woburn, MA, USA) and pu-
rified for library preparation using Agencourt AMPure XP beads (Beckman Coulter, 
Fullerton, CA, USA) following the manufacturer’s protocol. Enrichment was carried out 
using the Agilent SureSelect Human All Exon V6 r2 kit (Agilent Technologies, Santa Clara, 
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with cardiac conduction disease (CCD). (a) Family pedigree. The open symbols represent unaffected
individuals and the filled symbols represent affected in ivi uals; symbols with a diagonal line repr sent
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deceased individuals; and the arrowhead designates the proband. An asterisk indicates family
members from whom DNA was available. The genotypes of the TNNI3K mutation are indicated
below each examined member: CC (homozygote); TC (heterozygote); number inside the circle denote
the number of individuals. (b) Sequencing chromatograms. Vertical arrows indicate the mutation
site. (c) Schematic of the human TNNI3K gene. The positions of coding exons (black) and UTRs
(white) are indicated. Black arrows indicate previously reported pathogenic variants and the red
arrow shows the novel variant c.1531T>C in exon 16. (d) Initial 3D structure of TNNI3K-WT (PDB-ID:
4YFI [29]) shown as a ribbon. Monomer I is shown in gray and monomer II in green. The Cα atoms
of Ser511 (red), Gly526 (blue), and Thr539 (blue) of monomer I are shown in spheres relative to
the ATP-binding pocket (orange surface) of monomer I. Gly526 and Thr539 are known TNNI3K
missense variants. (e) TNNI3K protein domain structure. Coiled coil domain (gray); functional
ankyrin repeat domains, ANK1–ANK10 (purple); kinase domain (orange), where the homozygous
mutation p.Ser511Pro resides (arrowed); and a serine-rich domain (spring green).
2.2. Whole Exome Capture and Sequencing
WES of two of the affected individuals (IV-3 and IV-5), their non-affected siblings (1V-4
and IV-6), and their parents (III-1 and III-2) (Figure 1a) were carried out at the Cologne
Center for Genomics (CCG, University of Cologne, Cologne, Germany). A genomic DNA
sample (1 µg) was sheared by fragmentation (Covaris, Woburn, MA, USA) and purified
for library preparation using Agencourt AMPure XP beads (Beckman Coulter, Fullerton,
CA, USA) following the manufacturer’s protocol. Enrichment was carried out using the
Agilent SureSelect Human All Exon V6 r2 kit (Agilent Technologies, Santa Clara, CA,
USA). Captured libraries were subjected to paired-end sequencing on an Illumina HiSeq
4000 system (Illumina, San Diego, CA, USA) using a paired end 2 × 75bp protocol. Base
calling and demultiplexing were performed using the Illumina CASAVA pipeline and v1.7.
Raw reads were mapped against the human reference genome hg38/GRCh38 (Genome
Reference Consortium Human GRCh38) using the BWA alignment algorithm [30]. To
reduce noise and false positive calls, PCR duplicates were removed using Picard, followed
by local and base quality score recalibration using the Genome Analysis Toolkit (GATK,
v3.6) [31]. Single nucleotide polymorphisms and short insertions/deletions (INDELs) were
called using tools including GATK HaplotypeCaller (v3.6), SAMtools mpileup (v1.6), and
Platypus (v0.8.1) [32–34]. Subsequently, base quality scores were recalibrated to correct
sequencing errors and experimental artifacts using GATK v3.6 [31]. The ExomeDepth,
Conifer, and XHMM algorithms were applied to detect copy number variants and ALLE-
GRO was used to identify regions with runs of homozygosity (ROH) [33,35–37]. Software
tools developed at CCG were also employed, including the COMBINE module, which uses
an INDEL normalization step to integrate INDEL calls in repetitive sequence environments,
and the FUNC module for a functional interpretation of variations. Exome sequencing
data were processed and analyzed using the Varbank V2.12 exome pipeline from CCG
(https://varbank.ccg.uni-koeln.de/varbank2/ (accessed on 3 November 2018)). The fol-
lowing criteria were applied to filter rare and homozygous variants: coverage > 5 reads;
quality score > 10; allele read frequency ≥ 75%; minor allele frequency (MAF) < 0.001 in gno-
mAD; in-house population allele frequency < 0.001; strand bias estimated using Fisher’s Ex-
act Test (FS) < 40; MQRankSum ≥ −5; QD > 5; MQ > 50; ReadPosRankSum ≥ −5; quorum
level indel = 1; mapping quality > 50; quorum level SNV = 2; splice site score change ≤ 15%;
and translation initiation site (+score change > 15%, −score change −15%) [38,39]. Analy-
sis focused on single nucleotide, non-synonymous, missense, loss-of-function, and splice
site variants, as well as short INDELs. The resulting gene lists were prioritized based
on scores obtained from the dbNSFP/dbSCSNV v3.4 databases (filtering was based on
normalized rank scores, which range from 0 = benign to 1 = pathogenic) and variants that
were located in regions with ROH [35,40]. Additionally, data from various public databases
(dbSNP; 1000 Genomes, dbVar) were used to determine the distribution of genetic vari-
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ants in large populations and disease-specific databases (commercial HGMD professional
database; ClinVar, OMIM) were screened to determine whether variants had any associated
phenotypes. High priority variants were validated by Sanger sequencing.
2.3. Sanger Sequencing Analysis
Primer pairs were designed using Primer 3 software. PCR products were directly
sequenced using a commercial service (Microsynth AG, Sankt Gallen, Switzerland). Segre-
gation analysis of DNA from all available family members was performed by bidirectional
Sanger sequencing to validate mutations and sequences were analyzed using DNASTAR
Lasergene12 (DNASTAR Inc., Madison, WI, USA). Primer sequences are listed in Table S1.
2.4. Molecular Dynamic Simulations
For the molecular dynamic (MD) simulation, the X-ray structure of wild-type (WT)
TNNI3K was retrieved from the Protein Data Bank (PDB; http://www.rcsb.org/; down-
load on 15 August 2020; PDB-ID: 4YFI) and converted into its biological oligomerization
state [29,41]. The mutant structure of TNNI3K (containing p.Ser511Pro) was built based on
the WT X-ray structure, with an introduction of the single-point mutation. The WT and mu-
tant structures were preprocessed using the Protein Preparation Wizard (SCHRÖDINGER®
2020-3) [42,43]. Bond orders were assigned, all hydrogen atoms were added to each struc-
ture, and termini were capped. Incomplete side chains and loops were calculated and
water molecules deleted. Heterogenetic states were generated at pH 7 ± 2. Hydrogen
bonding networks were optimized by minimization of sampled hydrogens [44]. Each
structure was minimized to a gradient of 0.05 using an OPLS3e force field. Finally, the
minimized structures were subjected to solvent-explicit all-atom MD simulations using
the GPU-accelerated SCHRÖDINGER® DESMOND software [45,46]. Each structure was
integrated in a minimized periodic simple point charged water model with an orthorhom-
bic box size of 10.0 Å × 10.0 Å × 10.0 Å and 0.15 M NaCl ions. Each solvated system was
minimized and relaxed using the default protocol of SCHRÖDINGER® Desmond. MD
simulations were carried out with periodic boundary conditions in the NPT ensemble
using OPLS3e force field parameters. Temperature and pressure were maintained at 300 K
and 1 atmospheric pressure, respectively, using Nose-Hoover temperature coupling and
isotropic scaling. The operation was followed by running a 1 µs NPT production simulation
for each structure, saved at the 1 ns interval. Three independent MD simulations were
conducted for each case.
Next, the WT and mutated structures were compared based on root mean square
deviation (RMSD) and root mean square fluctuation (RMSF). Residue-residue contacts
between WT and mutant structures were monitored over the course of the last 200 ns of the
simulation time using the trajectory_asl_monitor.py script supported by SCHRÖDINGER®.
A contact was defined as a distance of < 5 Å between the centers of masses of defined
contact residue pairs. For each residue contact pair, the fraction of the simulation time in
which the residues were in contact was calculated as a mean of triplicate measurements.
Interaction energy values between two monomers for the WT and mutant structures were
computed using the Molecular Mechanics (MM)/Generalized Born Surface Area (GBSA)
method implemented in SCHRÖDINGER®. The average binding free energy (∆G_bind),
based on MM/GBSA, was calculated using the SCHRÖDINGER® Desmond command-
line thermal_mmgbsa.py script. During the MM/GBSA calculation, the last 200 ns MD
simulation trajectory (every 10th snapshot) was used as an input to compute the average
binding free energy. All heatmaps and plots were generated using GraphPad Prism version
9.0.0 for Windows (GraphPad Software, San Diego, CA USA, www.graphpad.com). Figures
were created using SCHRÖDINGER® Meastro 2020-3 [47].
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3. Results
3.1. Clinical Features
Early onset cardiac conduction disease (CCD) was clinically diagnosed in four mem-
bers of a Pakistani family (Figure 1a). The proband (IV-3) was a 22-year-old female with
a cardiac conduction defect and no underlying structural heart anomalies. A 24 h Holter
recording revealed mild sinus bradycardia with an average heart rate of 55 beats per minute
(bpm) at rest (range: 24–110) and sinus tachycardia of 160 bpm during exercise. Standard
12-lead ECG recorded at rest showed changes in the right bundle branch block and left
anterior fascicular block (RBBB/LAFB) with a bifascicular block. In individual IV-5, the
24 h Holter monitor recorded bradycardia with an average heart rate of 56 bpm and tachy-
cardia of 160 bpm; however, the echocardiogram revealed a restrictive perimembranous
ventricular septal defect with bilateral shunt. This patient died during this study due to
sudden cardiac arrest (SCA). In addition, two other siblings (IV 1 and IV 2) who had a
history of CCD died due to SCA at 26 and 23 years-of-age, respectively. Both parents and
healthy siblings were assessed for CCD but no relevant clinical features were detected.
Clinical data are presented in Table 1.
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Note: ID indicates identification; age at most recent evaluation in years (y); HR, sinus heart rate; b.p.m, beats per minute; NAD, no
abnormality detected; hyphen, no information, not present; SB, sinus bradycardia; Tach, Tachycardia; RBBB, right bundle branch block;
PRWP, poor R wave progression; BFB, bifascicular block; LVH, left ventricular hypertrophy; LAD, left axis deviation; LAFB, left anterior
fascicular block; HF, heart failure; SCA, sudden cardiac arrest; N, no; A, affected; U, unaffected; CC, homozygous mutant genotype; and TC,
heterozygous genotype.
3.2. Exome Sequencing Reveals a Pathogenic TNNI3K Variant
To uncover the underlying genetic cause of CCD in the family, we performed exome
sequencing in all available individuals, including two affected individuals, their parents,
and two healthy siblings (Figure 1a). We assumed an autosomal-recessive mode of in-
heritance because of the consanguinity of the healthy parents. After applying filtering
criteria as described in Section 2.2, a total of 81 rare genetic variants, including 79 non-
synonymous and two synonymous variants, were identified (Figure S1). The identified
variants spanned 69 protein coding genes and seven non-coding genes. Among the vari-
ants, eight co-segregated with the phenotype in the pedigree (Table S2). Candidate variants
were further screened by filtering within regions containing runs of homozygosity (ROH)
(Table S3). Of the three resulting candidate variants, the TTLL7 (NM_001350215.1) missense
variant is predicted to lead a serine to alanine change in a moderately conserved amino
acid, which lies outside of protein domains with known functions; TTLL7 is expressed at
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high levels in the mammalian nervous system. The MET (NM_000245.3, NM_001324402.1)
missense variant (rs545332056) changes an alanine to serine at position 319; this is a highly
conserved amino acid but reported in ClinVar (CA4448049) as of uncertain significance.
Interestingly, a homozygous missense mutation (Phe841Val) in MET was reported in a
Pakistani family with hearing impairment; however, no such phenotype was detected in
any affected individuals in the current study. The TNNI3K (NM_015978.2) serine residue at
position 511 is highly conserved in TNNI3K orthologues; accordingly, p.Ser511Pro is classi-
fied as “damaging” based on SIFT and Polyphen2 scores (Figure S2, Table S3). It also had
very high dbNSFP and phred-scaled CADD (v1.3) scores of 0.79 and 26.9, respectively, con-
sistent with pathogenicity (Table S3). Moreover, mutations in TNNI3K have also previously
been linked to the conduction heart disease spectrum (MIM 616117) (Table S4). Therefore,
the variant in TNNI3K is the most likely causative candidate for the phenotype under
investigation. The identified variant is an extremely rare homozygous variant that has not
been reported in a heterozygous/homozygous state in publicly available exome/genome
databases. Furthermore, it was absent from 110 exomes from Pakistani families with
various heart diseases and in exome sequence data from 50,000 UK Biobank participants.
3.3. In Silico Molecular Dynamic Simulation
3.3.1. p.Ser511Pro Influences TNNI3K Structural Fluctuation
To understand the effect of p.Ser511Pro on the structural and dynamic properties
of the protein, we conducted three independent 1 µs MD stimulations on the wild type
and mutant structures. The X-ray structure of TNNI3K with the lowest resolution (PDB-
ID: 4YFI [29]), containing amino acids Glu441 to Ile726 for monomer I (chain A) and
amino acids Gly451 to Met721 for monomer II (chain B), was used for the analysis of
the wild type model (TNNI3K-WT; Figure 1d). The mutant model (TNNI3K-S511P) was
obtained by introducing a point mutation (p.Ser511Pro) into TNNI3K-WT. The resulting
RMSDCα values of the MD simulations indicated that both models reached an equilibrium
state within a simulation time of 1 µs (Figure S3a). The distinct conformational states
sampled for both models showed no major differences (Figure S3b). Structural fluctuation
of TNNI3K-P511S was comparable to that of TNNI3K-WT over the entire lengths of the
models (average RMSFCα: 1.0 Å (TNNI3K-WT) and 1.1 Å (TNNI3K-S511P); Figure 2a). The
only pronounced differences were seen in the ATP-binding pocket of monomer I (Leu495-
Leu496) and in the dimer interface of monomer II (Thr637, Met677, and His680-Ile682).
All other regions exhibited changes smaller than the standard deviation or changes below
0.5 Å.
3.3.2. p.Ser511Pro Affects the Local Hydrogen Bonding Network and Protein Surface
Hydrophobicity of TNNI3K
Next, we investigated the local effect of p.Ser511Pro, which is located in helix 2
(Lys500-Asn517). Ser511 formed one hydrogen bond from its backbone nitrogen to the
backbone oxygen of Cys507 and a second hydrogen bond from its side chain hydroxyl
oxygen to the backbone oxygen of Cys507 throughout the simulation time (Figure 2b).
Interestingly, p.Ser511Pro cannot form a hydrogen bond to Cys507 because of its specific
structure. Furthermore, the protein surface of TNNI3K-S511P was more hydrophobic than
that of TNNI3K-WT (Figure 2c,d).




Figure 2. Root mean square fluctuation, hydrogen bond analysis, and electrostatic surface potential 
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urements were performed for the Cα carbon atoms. (b) Hydrogen bond analysis. Length of the hy-
drogen bonds between Cys507 and Ser511 in TNNI3K-WT as a mean value of three independent 
MD simulations (1 µs). (c,d) A comparison of the electrostatic surface potential of TNNI3K-WT (c) 
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map. (a) Comparison of root mean square fluctuation values of TNNI3K-WT (green) and TNNI3K-
S511P (blue) during three independent 1 µs MD simulations with error bars. Alignments and
measurements were performed for the Cα carbon atoms. (b) Hydrogen bond analysis. Length of the
hydrogen bonds between Cys507 and Ser511 in TNNI3K-WT as a mean value of three independent
MD simulations (1 µs). (c,d) A comparison of the electrostatic surface potential of TNNI3K-WT (c)
and TNNI3K-S511P (d), demonstrating that p.Ser511Pro leads to a ore hydr phobic protein surface
(“red white blue” color ramp with a minimum of −0.3 and a maximum of 0.3).
3.3.3. p.Ser511Pro Affects the Structure of Helix 2 and the ATP-Binding Pocket
To analyze the effects of p.Ser511Pro on each monomer structure, a comparative
time-dependent intra-contact analysis was performed for TNNI3K-WT and TNNI3K-S511P
between the amino acids of helix 2 and the amino acids of the corresponding monomer. As
illustrated in Figure 3a,b, the largest contact difference of 97% (TNNI3K-WT: 98%; TNNI3K-
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S511P: 1%) in monomer I was found for the contact between Cys507 and Ile512, which
are neighboring amino acids of S511 and S511P, respectively. For monomer II, the largest
contact difference (91%) was also between Cys507 and Ile512 (TNNI3K-WT: 97%; TNNI3K-
S511P: 6%). In monomer I, the distances between the Cα atoms of Ile512 and Cys507 were
6.02 ± 0.18 Å for TNNI3K-WT and 7.05 ± 0.40 Å for TNNI3K-S511P, respectively. Similar
observations were made for monomer II (TNNI3K-WT: 6.03 ± 0.19 Å; TNNI3K-S511P:
6.99 ± 0.28 Å). These data imply that p.Ser511Pro causes minimal stretching of helix 2 in
the mutant region (Cys507-Ile512) relative to TNNI3K-WT. Intriguingly, >±50% differences
were further observed only for contacts between helix 2 amino acids, namely Asp502,
Val503, Phe506 and Cys514, in monomer I and amino acids of the ATP-binding pocket
(Phe448, Leu452, Tyr497, and Phe535; Figure 3a,b).
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Figure 3. Average intra/inter residue-residue contact maps and MM/GBSA analysis. (a) Contact
map of the residues of helix 2 in monomer I and the residues of the corresponding monomer, and
(b) residues of helix 2 in monomer II and the residues of the corresponding monomer. Each point
represents the mean of the average residue-residue contact difference between TNNI3K-WT and
TNNI3K-S511P over the last 200 ns from the three independent MD simulations (spectrum range
from green to white to blue, from 100% to −100% contact; green means more contacts in TNNI3K-WT
and blue means more contacts in TNNI3K-S511P). (c) Contact map between residue-residue pairs in
the dimer interface for TNNI3K-WT vs. TNNI3K-S511P. The contact spectrum ranging from green to
white to blue, representing 100% to −100% contact, where green indicates more contacts in TNNI3K-
WT and blue indicates more contacts in TNNI3K-S511P. Each point represents the mean difference
in the residue-residue contact over the last 200 ns from the three independent MD simulations.
(d) MM/GBSA analysis applied for dimerization of TNNI3K. Every 10th snapshot of the last 200 ns
of the MD simulation was used. Each violin plot represents the mean from the three independent
simulations (95% confidence interval).
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3.3.4. p.Ser511Pro Creates a Less Favorable Binding Site at the Dimer Interface
In addition, amino acids at the dimer interface (Ile584-Asn590 and Glu609-Leu613;
Figure S4) were located within a 10 Å radius around helix 2. Therefore, differences of
≤±30% were measured in intra contact analysis. The largest difference (−30%) was for
the contact between Ile512 and Phe612 in monomer I (TNNI3K-WT: 70%; TNNI3K-S511P:
100%; Figure 3a,b). The Cα atom distance between Ile512 and Phe612 in monomer I was
10.29 ± 1.48 Å for TNNI3K-WT and 7.67 ± 0.68 Å for TNNI3K-S511P. Interestingly, Ile512
and Phe612 in monomer II showed a difference of only 2% (TNNI3K-WT: 100%, TNNI3K-
S511P: 98%) with a Cα distance of 10.01 ± 0.62 Å for TNNI3K-WT and 10.17 ± 0.75 Å
for TNNI3K-S511P. These findings indicate that for monomer I, Phe612, located in the
dimer interface loop (Glu609-Leu613), is brought closer to helix 2 by the p.Ser511Pro
mutation. Therefore, we hypothesized that p.Ser511Pro might indirectly influence the
dimerization of TNNI3K. To assess this, we conducted a comparative time-dependent
inter-contact analysis between the dimer interface amino acids (monomer I/II: Ile584-
Ans590, Glu609-Leu653, Leu668-His681, and Trp702-Arg709; Figure S4) of TNNI3K-WT
and TNNI3K-S511P in monomer I, an amino acid close to Phe612, and Asn627 in monomer
II (TNNI3K-WT: 89.50%; TNNI3K-S511P: 5.67%). By contrast, Glu609 in monomer II
and Asn627 in monomer I had contact values of 39.00% in TNNI3K-WT and 31.33% in
TNNI3K-S511P, representing a difference of 7.67%. This is not surprising as Phe612 and
Glu512 only showed strong differences in monomer I and not in monomer II. Similar
results were observed for the contact between Cys705 and Asp676 (Cys705 monomer I
−Asp676 monomer II: 59.33%; Asp676 monomer I −Cys705 monomer II: 5%). By contrast,
the contact between Arg587 monomer I and Thr622 monomer II showed similar effects to
those of their respective counterparts (Arg587 monomer I −Thr622 monomer II: 60.66%;
Thr622 monomer I −Arg587 monomer II: 42.33%). Conversely, for Arg641 monomer I and
Gln639 monomer II, more contacts were measured in TNNI3K-S511P than in TNNI3K-
WT (Arg641 monomer I. −Gln639 monomer II: −58.66%; Gln639 monomer I −Arg641
monomer II: −10.33%). For all other 17 contacts, the counterpart went in the opposite
direction. Together, these results indicate that the mutation affects the dimer-binding
interface. To better understand the observed effects of the mutations on the dimer interface,
we also employed the MM/GBSA method to calculate the binding energy between the
two monomers; this is a simple post-processing technique in which the free energy of a
state is calculated from the internal energy (MM) of the molecule and its interaction with
an implicit representation of the solvent (GBSA). Although this method does not estimate
the unfavorable entropy contribution to the binding and hence is less accurate than, for
example, free energy perturbation, thermodynamic integration, or Bennett acceptance ratio,
it avoids the enormous costs associated with other techniques and is consequently used
often for large systems [48–50]. We considered the MM/GBSA values determined here as
scores indicating predictive power in the ranking rather than representing quantitative
agreement with experimentally observed affinities. The calculated MM/GBSA values
(Figure 3d) indicate that the observed structural change leads to a less favorable total free
binding energy and thereby to a less favorable bound state.
4. Discussion
In the present study, we identified a recessive CCD-associated sequence alteration,
c.1531T>C;(p.Ser511Pro), in TNNI3K in a consanguineous Pakistani family. This variant
affects an amino acid that is completely evolutionarily conserved (Figure S2) and which is
predicted to be a causative mutation using in silico prediction tools. The missense mutation
co-segregated with cardiac conduction disease in the family with complete penetrance
(Figure 1a). It resides within the kinase domain of TNNI3K, which is highly conserved
across species. This study aimed to gain insights into the effect of this mutation on the
kinase domain and to assess its functional and structural consequences using long-term
MD simulations.
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The MD simulations provided detailed information about the structural fluctuation of
the protein, the intra and intermolecular amino acid contacts, and the energetic properties
of the mutant structure relative to the wild type. In the wild type model, Ser511 forms
two hydrogen bonds with Cys507; one from its backbone nitrogen to the backbone oxygen
of Cys507 and the other from its side-chain hydroxyl oxygen to the backbone nitrogen
of Cys507. Pro511 cannot mimic the hydrogen bond network of Ser511 due to its unique
structural property. This conformational change introduced by the mutation stretches helix
2 into the region containing the mutation (p.Cys507-Ile512) in both monomers.
Changes in both structural fluctuation (Figure 2a) and amino acid contacts (Figure 3a,b)
were also observed in the monomer I ATP-binding pocket adjacent to helix 2. As amino
acid orientation and interactions in the ATP-binding pocket are critical for the activity of the
complex [51], these findings suggest that the mutation alters the ATPase activity of TNNI3K
and therefore causes a reduction in its catalytic phosphorylation activity. Interestingly, our
hypothesis is in line with the findings of Podliesna et al. [26] who observed a reduction
or loss of autophosphorylation activity in all previously reported human TNNI3K kinase
domain mutants (p.Gly526Asp and p.Thr539Ala). They postulated that affected individuals
would exhibit reduced TNNI3K protein levels and kinase activity, eventually leading to a
cardiac excitation conduction defect [26].
Moreover, using MD, we observed that the mutation in monomer I brings Phe612,
located within a loop (Ala605 to Glu634) in the dimer interface, closer to helix 2. Further
intercontact analysis confirmed changes in the region of the dimer interface. Together with
the results of MM/GBSA-based analysis, we hypothesize that the change in the amino
acid interaction pattern at the dimer interface results in a more energetically unfavorable
dimer arrangement in TNNI3K-S511P. Further analyses using a heterozygous dimer will
be required to obtain a deeper understanding of the one-sided effects of the mutation in
the monomer I.
The mutation-induced change in helix 2 also influenced the hydrophobicity of the
TNNI3K protein surface. It is known that the surfaces of proteins in an aqueous envi-
ronment are predominantly composed of hydrophilic amino acids [52]. Therefore, the
substitution of the polar serine to a non-polar proline led to an increase in the hydropho-
bicity of the protein surface (Figure 2c,d). Changes in surface hydrophobicity are closely
associated with protein misfolding and aggregation, which are pathological hallmarks
of many human diseases such as Alzheimer’s disease, Parkinson’s disease, and heart
diseases [16,53]. Interestingly, previous studies have reported that a heterozygous TNNI3K
missense mutation leading to a Gly526Asp substitution causes the formation of insolu-
ble protein aggregates in in vitro analysis and a hydrophobic spot in the kinase domain
surface in in silico protein surface analysis. Additionally, a dominantly negative mutation
in TNNI3K (Gly526Asp) has been shown to deplete TNNI3K in ventricular cardiomy-
ocytes [16]. Here, we show that a bi-allelic p.Ser511Pro mutation resulted in a recessive
conduction defect in a Pakistani family.
Hitherto, disease-causing TNNI3K variants have been reported to be due to heterozy-
gous mutations (Table S4). Symptoms manifest with age, with disease onset in CCD
patients ranging from 18 to 84 years [16,25–27]. Interestingly, in the current study, the
parents, who were obligate carriers, and heterozygous siblings were all asymptomatic; no
subclinical evidence of cardiac conduction system dysfunction was observed. However, in
homozygous patients, disease symptoms appeared at a very early age and patients had a
shorter life expectancy than those in previous reports. Two patients (IV-I and IV-2) had al-
ready died at 26 and 23 years-of-age, respectively. A plausible explanation for these results
may be autozygosity, which increases the homozygous occurrence of alleles associated
with a dominant inheritance pattern. The genetic background and/or modifier loci could
also have a role in increasing the severity of the disease [54–56].
To date, no studies have been conducted in the Pakistani population to investigate the
genetics underlying the cardiac system, except for a report of a homozygous mutation in
CACNA1D, which causes deafness with bradycardia syndrome [57]. Therefore, to the best
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of our knowledge, this is the first reported recessive TNNI3K mutation, as well as the first
TNNI3K mutation of all detected in the Pakistani population.
Clinical implications: First, it is important to understand the underlying pathomecha-
nisms of a disease; this is mainly facilitated by the identification of pathogenic mutations,
especially in families, with a genetic background that is not frequently studied. Regardless,
knowledge of a pathogenic mutation in a family helps in the early diagnosis of asymp-
tomatic family members.
5. Conclusions
In summary, the p.Ser511Pro mutation identified in TNNI3K leads to a different
hydrogen bond network in helix 2, which affects the contacts between amino acids of
helix 2 and those of the ATP-binding pocket. It also affects the dimer interface, resulting
in an unfavorable binding energy. As the p.Ser511Pro substitution results in greater
hydrophobicity and loss of interaction with the ATP-binding pocket, Ser511 clearly plays
an important role in orienting the TNNI3K dimer; however, these new findings require
functional validation. Overall, our study contributes to the TNNI3K mutation spectrum
and will inform genetic counseling for CCD in Pakistani families.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/genes12081282/s1: Figure S1: Filtering and prioritizing homozygous genetic variants;
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of TNNI3K-WT (green) and TNNI3K-S511P (blue) during three independent 1 µs MD simulations;
Figure S4: Dimer interface region of TNNI3K-WT (PDB-IDc: 4YF); Table S1: Primer sequence related
to Sanger validation. Table S2: List of homozygous rare variants segregated with the observed
phenotype; Table S3: List of primary homozygous candidate variants in runs of homozygosity (ROH)
regions; and Table S4: The geographical distribution of TNNI3K pathogenic variants.
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